May 28, 2016
Edinburgh, UK

Solid at the 8th Annual ECRD Meeting

In May, Solid had the honor of participating in the 8th European Conference on Rare Diseases & Orphan Products in Edinburgh, which is organized bi-annually by the European Organisation for Rare Diseases (EURODIS) and DIA Europe, Middle East & Africa.

ECRD is one of the foremost meetings of the rare disease community, offering those impacted by rare diseases and those committed to solving them with the opportunity to share ideas, concerns and progress.

During the meeting, Carl Morris, Ph.D., Solid’s vice president of Research & Development, showcased why Solid fits naturally into the conference’s theme of “Game Changers in Rare Disease.”  During a panel discussion called “Launch Platforms,” Dr. Morris discussed Solid’s unique business model that focuses solely on solving Duchenne muscular dystrophy, regardless of technology or modality. Dr. Morris also discussed our novel strategies to partner with the community and develop tested collaborations. 

“It is through working together, sharing our learnings and progress, and listening to the experiences of others that we will be successful in our goal to address all facets of Duchenne muscular dystrophy and improve the quality of life for those impacted by the disease,” said Dr. Morris.

To learn more about our approach to therapy and assistive device development,

Click Here

Related news

Oct14

It has been an exciting and emotional time for our Duchenne muscular dystrophy (DMD) community.

Sep20

Solid Biosciences congratulates Sarepta on the U.S. approval of the first therapy for Duchenne muscular dystrophy.

Sep08

Solid Biosciences joined the Jett Foundation and other members of the local Cambridge, MA community to observe World Duchenne Awareness Day.

Jun17

Solid Biosciences Community Update Q2 2016

Jun13

Grants from the charities Duchenne Now, Save Our Sons and Fight DMD will support important work in furthering Solid’s gene therapy and disease modifying therapy programs.

Jun09

The biologic candidate LTBP4 has the potential to promote muscle health and reduce fibrosis in patients with Duchenne muscular dystrophy.

Dec08

Debiopharm International SA and Solid Biosciences, LLC, announce a collaboration to explore the use of Alisporivir (Debio 025) in muscular dystrophy.

Pages

More information about Solid?

Please subscribe to receive our latest news